By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Miscellaneous metabolic agents > Zokinvy > Zokinvy Dosage
Miscellaneous metabolic agents
https://themeditary.com/dosage-information/zokinvy-dosage-4578.html

Zokinvy Dosage

Drug Detail:Zokinvy (Lonafarnib [ loe-na-far-nib ])

Generic Name: LONAFARNIB 50mg

Dosage Form: capsule

Drug Class: Miscellaneous metabolic agents

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Recommended Dosage

  • The starting dosage of ZOKINVY for patients with a BSA of 0.39 m2 and above is 115 mg/m2 twice daily with morning and evening meals (see Table 1) to reduce the risk of gastrointestinal adverse reactions [see Adverse Reactions (6.1)]. An appropriate dosage strength of ZOKINVY is not available for patients with a BSA of less than 0.39 m2 [see Indications and Usage (1)].
  • After 4 months of treatment, increase the dosage to 150 mg/m2 twice daily with morning and evening meals (see Table 2).
  • Round all total daily dosages to the nearest 25 mg increment (see Table 1 and Table 2).
  • If a dose is missed, take the dose as soon as possible with food, up to 8 hours prior to the next scheduled dose. If less than 8 hours remains before the next scheduled dose, skip the missed dose, and resume taking ZOKINVY at the next scheduled dose.

Table 1 provides the BSA-based dosage recommendations for the starting dosage of 115 mg/m2 twice daily.

Table 1: Recommended Dosage and Administration for 115 mg/m2 Body Surface Area-Based Dosing
BSA(m2) Total Daily
Dosage Rounded
to Nearest 25 mg
Morning Dosing
Number of Capsule(s)
Evening Dosing
Number of Capsule(s)
ZOKINVY
50 mg
ZOKINVY
75 mg
ZOKINVY
50 mg
ZOKINVY
75 mg
0.39 - 0.48 100 1 1
0.49 - 0.59 125 1 1
0.6 - 0.7 150 1 1
0.71 - 0.81 175 2 1
0.82 - 0.92 200 2 2
0.93 – 1 225 1 1 2

Table 2 provides the BSA-based dosage recommendations for the dosage of 150 mg/m2 twice daily.

Table 2: Recommended Dosage and Administration for 150 mg/m2 Body Surface Area-Based Dosing
BSA(m2) Total Daily
Dosage Rounded
to Nearest 25 mg
Morning Dosing
Number of Capsule(s)
Evening Dosing
Number of Capsule(s)
ZOKINVY
50 mg
ZOKINVY
75 mg
ZOKINVY
50 mg
ZOKINVY
75 mg
0.39 - 0.45 125 1 1
0.46 - 0.54 150 1 1
0.55 - 0.62 175 2 1
0.63 - 0.7 200 2 2
0.71 - 0.79 225 1 1 2
0.8 - 0.87 250 1 1 1 1
0.88 - 0.95 275 2 1 1
0.96 – 1 300 2 2

Dosage Modifications for Gastrointestinal Adverse Reactions

For patients who have increased their dose of ZOKINVY to 150 mg/m2 twice daily and are experiencing repeated episodes of vomiting and/or diarrhea resulting in dehydration or weight loss, ZOKINVY can be dose reduced to the starting dose of 115 mg/m2 twice daily (see Table 1). Ensure ZOKINVY is taken with the morning and evening meals and an adequate amount of water.

Dosage Modifications for Drug Interactions

CYP3A Inhibitors
If concomitant use of ZOKINVY with a weak CYP3A inhibitor is unavoidable [see Warnings and Precautions (5.1), Drug Interactions (7.1)]:

  • Reduce to or continue ZOKINVY at the starting dosage of 115 mg/m2 twice daily (see Table 1).
  • Resume the previous ZOKINVY dosage 14 days after discontinuing the concomitant use of the weak CYP3A inhibitor.

Temporary Discontinuation for Midazolam Use

Temporarily discontinue ZOKINVY for 10 to 14 days before and 2 days after administration of midazolam [see Contraindications (4), Drug Interactions (7.2)].

Preparation and Administration Instructions

Administer ZOKINVY orally with the morning and evening meals.

Patients Able to Swallow Capsules

  • Administer ZOKINVY capsules whole with a sufficient amount of water. Do not chew the capsules.

Patients Unable to Swallow Capsules

  • The entire contents of ZOKINVY capsules can be mixed with Ora Blend SF® or Ora-Plus® or, for patients unable to access or tolerate Ora Blend SF or Ora-Plus, the contents of ZOKINVY capsules can be mixed with orange juice or applesauce (see preparation instructions below).
  • Do not mix with juice containing grapefruit or Seville oranges [see Contraindications (4), Drug Interactions (7.1)].
  • The mixture must be prepared fresh for each dose and be taken within approximately 10 minutes of mixing.

Preparation of Dose in Ora Blend SF, Ora-Plus, or Orange Juice

  1. For each capsule, empty contents of the capsule into a container containing 5 mL to 10 mL of the liquid.
  2. Mix thoroughly with a spoon.
  3. Consume entire serving.

Preparation of Dose in Applesauce

  1. For each capsule, empty contents of the capsule into a container containing 1 teaspoonful to 2 teaspoonfuls of applesauce.
  2. Mix thoroughly with a spoon.
  3. Consume entire serving.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by